- GBI & PARTNERS
- Argentina is second market to wave through Eli Lilly’s Verzenio
Argentina is second market to wave through Eli Lilly’s Verzenio
Argentina’s National Administration of Drugs, Foods and Medical Devices (ANMAT) this week cleared Eli Lilly’s breast cancer treatment Verzenio (abemaciclib) for marketing, as GBI analysis reveals. The orally administered therapy is approved for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer.
Cyclin-dependent kinases 4 and 6 (CDK4 and CDK6) promote phosphorylation of the retinoblastoma protein (Rb), cell cycle progression, and cell proliferation in estrogen receptor-positive (ER+) breast cancer cells. Verzenio is a protein kinase inhibitor that selectively acts on CDK4 and CDK6, thus preventing Rb phosphorylation and stalling the cell cycle, which results in tumor cell senescence and apoptosis.
GBI analysis reveals that ANMAT’s approval is the second for Verzenio in Latin America after the drug obtained market clearance earlier this year in Brazil, where it is commercialized under the brand name Verzenios, as GBI reported. As is the case in Brazil, Verzenio will compete in the Argentina market with Pfizer’s CDK4/CDK6 inhibitor Ibrance (palbociclib), which was launched in the country in 2016, according to GBI SOURCE.